HDAC3 and neoplasm: More importantly, our findings suggest that the combination of Rictor/mTORC2‐HDAC3 inhibitors and glutamine uptake inhibitors might be an effective therapeutic strategy to retard tumor growth and prevent progression in patients with advanced malignant tumors.